Everolimus

31 trials 17 recruiting LOncology Orphan designation

Filter these 31 trials by condition, phase, country and more.

Open in Search →

31 Registered trials

17 Recruiting

9 Completed trials

28 Sponsors

18 Countries

Phase III

Phase II

Phase IV

Phase III: 12 Phase II/III: 2 Phase II: 8 Phase I/II: 1 Phase III/IV: 1 Phase IV: 5 Phase I (Other): 2

Oversight events:

2 serious breaches 3 temporary halts across 3 trials

View oversight register →

Indications tested

Gastroenteropancreatic neuroendocrine tumour disease 4 Hormone receptor positive HER2 negative breast cancer 2 Breast cancer metastatic 2 Pancreatic neuroendocrine tumour 2 Ovarian cancer 1 Acute graft versus host disease 1 HER2 negative breast cancer 1 Neuroendocrine tumour 1 Renal failure 1 Breast cancer female 1 Meningioma 1 Breast cancer 1

Sponsors using this IMP

Odense University Hospital 3 Institut Gustave Roussy 2 ITM Solucin GmbH 2 Pfizer Inc. 2 Universitair Medisch Centrum Groningen 2 Antwerp University Hospital 1 Arvinas Estrogen Receptor Inc. 1 Centre Hospitalier Regional De Marseille 1 Champalimaud Clinical Centre 1 CHRU De Nancy 1 Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi 1 Exelixis Inc. 1

All trials — page 2

31 total

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE) Ended

2023-510444-21-00 Phase III 9 countries ITM Solucin GmbH
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free … Ended

2024-516198-61-00 Phase III 2 countries Unicancer
PREPARE-iVAC Ended

2023-503894-39-00 Phase III/IV 1 country Universitair Medisch Centrum Groningen
A Phase 1b Trial of ARV-471 in Combination with Everolimus in Patients with ER+, HER2– Advanced or Metastatic Breast Cancer Ended

2024-513284-30-00 Phase I (Other) 1 country Arvinas Estrogen Receptor Inc.
OPTIMIZE Ended

2024-516509-22-00 Phase IV 2 countries Universitair Medisch Centrum Groningen
Roll-over study in patients with TSC and refractory seizures who are judged by the Investigator to benefit from continued treatment with eve… Ended

2024-516746-19-00 Phase III 1 country Novartis Pharma AG
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan… Ended

2023-506487-13-00 Phase III 14 countries Pfizer Inc.

Showing 25–31 of 31 trials

← All drugs A–Z